AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The Chronic Kidney Disease Registry Platform Study, officially titled as such, is a multicenter, prospective, observational study led by AstraZeneca. Its primary aim is to establish a registry platform by collecting comprehensive data on chronic kidney disease (CKD) patients in China. This includes demographics, clinical characteristics, and treatment patterns to identify gaps in current practices and develop risk prediction models for CKD progression.
This study does not involve any specific interventions or treatments but focuses on observational data collection. It aims to gather insights into CKD with high proteinuria and CKD with hypertension, among other subpopulations.
The study is designed as a cohort observational model with a prospective time perspective. It will track approximately 5,000 CKD patients over three years, collecting baseline and annual follow-up data to support its objectives.
The study began on November 28, 2023, with primary completion expected by 2027. The last update was submitted on August 11, 2025. These dates highlight the study’s timeline and its ongoing nature.
The implications for AstraZeneca’s stock performance could be significant, as successful outcomes may enhance their reputation in the nephrology field. However, the impact on investor sentiment will depend on the study’s findings and their alignment with industry needs and competitor actions.
The study is currently recruiting, and further details can be accessed on the ClinicalTrials portal.